Literature DB >> 24379616

Immunological alterations in hepatitis C virus infection.

Vincenza Calvaruso1, Antonio Craxì1.   

Abstract

A higher prevalence of immunological processes has recently been reported in patients with hepatitis C virus (HCV) infection, focusing the attention of physicians and researchers on the close association between HCV and immune disorders. HCV lymphotropism represents the most important step in the pathogenesis of virus-related immunological diseases and experimental, virologic, and clinical evidence has demonstrated a trigger role for HCV both in systemic autoimmune diseases, such as rheumatoid arthritis, Sjögren syndrome, hemolytic anemia and severe thrombocytopenia, and in organ-specific autoimmune diseases, such as autoimmune hepatitis, thyroid disorders and diabetes. This review will outline the principal aspects of such HCV-induced immunological alterations, focusing on the prevalence of these less characterized HCV extrahepatic manifestations.

Entities:  

Keywords:  Autoantibody; Cytopenia; Extrahepatic manifestation; Hepatitis C virus; Immune disorders

Mesh:

Year:  2013        PMID: 24379616      PMCID: PMC3870544          DOI: 10.3748/wjg.v19.i47.8916

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  82 in total

1.  HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant alpha2b-interferon therapy.

Authors:  J García-Suárez; C Burgaleta; N Hernanz; F Albarran; P Tobaruela; M Alvarez-Mon
Journal:  Br J Haematol       Date:  2000-07       Impact factor: 6.998

2.  Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection.

Authors:  C Betterle; P Fabris; R Zanchetta; B Pedini; G Tositti; E Bosi; F de Lalla
Journal:  Diabetes Care       Date:  2000-08       Impact factor: 19.112

3.  Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy: a case of Th1-mediated disease?

Authors:  E Bosi; R Minelli; E Bazzigaluppi; M Salvi
Journal:  Diabet Med       Date:  2001-04       Impact factor: 4.359

4.  Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon.

Authors:  S Piquer; C Hernández; J Enriquez; A Ross; J I Esteban; J Genescà; E Bonifacio; M Puig-Domingo; R Simó
Journal:  J Lab Clin Med       Date:  2001-01

5.  Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: detection by suppression-subtractive hybridization.

Authors:  R Patzwahl; V Meier; G Ramadori; S Mihm
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

6.  Autoimmune hemolytic anemia in treatment-naïve chronic hepatitis C infection.

Authors:  R Srinivasan
Journal:  J Clin Gastroenterol       Date:  2001-03       Impact factor: 3.062

Review 7.  Hepatitis C virus infection mimicking primary Sjögren syndrome. A clinical and immunologic description of 35 cases.

Authors:  M Ramos-Casals; M García-Carrasco; R Cervera; J Rosas; O Trejo; G de la Red; J M Sánchez-Tapias; J Font; M Ingelmo
Journal:  Medicine (Baltimore)       Date:  2001-01       Impact factor: 1.889

8.  Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy.

Authors:  A Matsumori; C Yutani; Y Ikeda; S Kawai; S Sasayama
Journal:  Lab Invest       Date:  2000-07       Impact factor: 5.662

9.  Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study.

Authors:  N Ganne-Carrie; A Medini; E Coderc; O Seror; C Christidis; S Grimbert; J C Trinchet; M Beaugrand
Journal:  J Autoimmun       Date:  2000-03       Impact factor: 7.094

10.  Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States.

Authors:  S H Mehta; F L Brancati; M S Sulkowski; S A Strathdee; M Szklo; D L Thomas
Journal:  Ann Intern Med       Date:  2000-10-17       Impact factor: 25.391

View more
  7 in total

Review 1.  Hepatitis C virus infection and thyroid autoimmune disorders: A model of interactions between the host and the environment.

Authors:  Francesca Pastore; Antonio Martocchia; Manuela Stefanelli; Pietro Prunas; Stefania Giordano; Lavinia Toussan; Antonio Devito; Paolo Falaschi
Journal:  World J Hepatol       Date:  2016-01-18

2.  Successful and Safe Long-Term Standard Antiviral Therapy in a Patient with "Explosive" Immune Response in Course of HCV-Related Liver Cirrhosis.

Authors:  Paolo Conca; Giovanni Cafaro; Amalia De Renzo; Antonio Coppola; Ernesto Cimino; Giovanni Tarantino
Journal:  Int J Mol Sci       Date:  2015-06-19       Impact factor: 5.923

3.  Prevalence and risk factors for patient-reported joint pain among patients with HIV/hepatitis C coinfection, hepatitis C monoinfection, and HIV monoinfection.

Authors:  Alexis Ogdie; Wyki Gina Pang; Kimberly A Forde; Bhangle D Samir; Lakeisha Mulugeta; Kyong-Mi Chang; David E Kaplan; Valerianna K Amorosa; Jay R Kostman; Rajender K Reddy; Ralph H Schumacher; Vincent Lo Re
Journal:  BMC Musculoskelet Disord       Date:  2015-04-19       Impact factor: 2.362

Review 4.  Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders.

Authors:  Cristiana Bianco; Elena Coluccio; Daniele Prati; Luca Valenti
Journal:  J Clin Med       Date:  2021-01-22       Impact factor: 4.241

Review 5.  Diagnostic Criteria of Oral Lichen Planus: A Narrative Review.

Authors:  Doina Iulia Rotaru; Diana Sofineti; Sorana D Bolboacă; Adriana E Bulboacă
Journal:  Acta Clin Croat       Date:  2020-09       Impact factor: 0.780

6.  Direct-Acting Antiviral Treatment of Patients with Hepatitis C Resolves Serologic and Histopathologic Features of Autoimmune Hepatitis.

Authors:  Camila C Simoes; Omar A Saldarriaga; Netanya S Utay; Ashley E Stueck; Sheharyar K Merwat; Shehzad N Merwat; Thomas D Schiano; Maria Isabel Fiel; Heather L Stevenson
Journal:  Hepatol Commun       Date:  2019-06-08

Review 7.  Natural Formulations: Novel Viewpoint for Scleroderma Adjunct Treatment.

Authors:  Shirin Assar; Hosna Khazaei; Maryam Naseri; Fardous El-Senduny; Saeideh Momtaz; Mohammad Hosein Farzaei; Javier Echeverría
Journal:  J Immunol Res       Date:  2021-06-24       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.